LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box/HDPE bottle

1. Name of the medicinal product

[HA620 trade name]¹ Lamivudine/Tenofovir Disoproxil Fumarate /300mg/300mg Tablets

2. Statement of active substance

Each tablet contains 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate (TDF) equivalent to 245 mg of tenofovir disoproxil or 136 mg of tenofovir.

3. List of excipients

Contains lactose

See patient information leaflet for further information.

4. Pharmaceutical form and contents

Film-coated tablets

30 tablets

100 tablets

5. Method and route of administration

Oral use

Read the patient information leaflet before use.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach and sight of children.

7. Other special warning(s), if necessary

8. Expiry date

EXP {MM/YYYY}

9. Special storage conditions

Do not store above 30°C.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

11. Name and address of the supplier

Micro Labs Limited # 31, Race Course Road Bangalore - 560001, Karnataka, India Tel: +91-80-2237 0451/57

Fax: +91-80-2237 0463

12. WHO Reference Number (Prequalification Programme)

HA620

13. Manufacturer's batch number

<Batch> {number}

14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

15. Instructions on use